Thalia Therapeutics plc (AIM:THAT), the AIM-quoted RNA therapeutics developer, said its proposed acquisition of Sanmirna Therapeutics and £2.75 million oversubscribed fundraise represent a transformational step, as shareholders prepare to vote on the deal at today's annual general meeting.
Chief executive, Dr David Solomon, told investors the transaction would accelerate the company's transition into a clinical-stage biotechnology business and significantly strengthen its RNA therapeutics pipeline.
Subject to shareholder approval, the acquisition will add miRisten, a Phase 1 clinical-stage microRNA therapeutic for acute myeloid leukaemia, to Thalia's portfolio.
It sits alongside the company's proprietary Nuvec delivery technology and a dual-targeting cardiovascular siRNA programme, creating what Solomon described as a diversified portfolio addressing multi-billion-dollar global markets in oncology and cardiovascular disease.
Topline data from the Phase 1 miRisten study is expected in the first half of 2027, ahead of preparation for phase II.
The trial remains open, though patient enrolment has been temporarily paused while the current cohort progresses through the study.
Solomon said funding is in place for planned work across the portfolio, including completion of the miRisten trial.
Immediate priorities are to integrate Sanmirna following completion of the acquisition, advance the cardiovascular programme towards IND-enabling studies and continue developing Nuvec as a differentiated RNA delivery platform.
"Thalia is entering an exciting new phase of development," Solomon said, adding that the board is focused on delivering a number of important value-creating milestones.
The AGM takes place at 11 am on Friday in London.
